Clinical Treatment Options for Vitiligo:
What You Need to Know
From light therapy to cutting-edge biologics — a clear-eyed look at every proven path to repigmentation.
Vitiligo treatment has evolved dramatically. Today’s options range from targeted light therapy to JAK inhibitors approved just in 2023 — giving dermatologists and patients more tools than ever before. This guide walks through every major clinical treatment, how it works, who it’s best for, and what to realistically expect.
Treatment Options, Explained
The gold standard. Emits 311nm wavelength, 2–3 sessions per week in a clinic. Effective on face, trunk and limbs. Suitable for widespread vitiligo. Up to 70% of patients achieve meaningful repigmentation.
Targeted laser for small, stubborn patches — especially on the face. Faster results than whole-body NB-UVB, but limited to localised areas. Often combined with topical therapy.
Psoralen + UVA light. Older approach, largely replaced by NB-UVB due to higher side-effect profile. Still used in some centres for resistant cases.
First-line treatment for small patches. Potent steroids (e.g., clobetasol) used in short cycles to minimise atrophy risk. Work by reducing local immune attack on melanocytes.
Non-steroidal alternative — ideal for sensitive areas like the face and neck. Preferred for children. Fewer long-term side effects than steroids.
First and only FDA-approved topical treatment specifically for vitiligo. A JAK1/2 inhibitor applied twice daily. Shown to repigment 30% of facial vitiligo area in clinical trials. Significant breakthrough for patients with facial patches.
Short-burst oral steroids (e.g., betamethasone mini-pulse) used to halt rapidly progressing vitiligo. Not a long-term solution — used to stabilise active disease before other treatments.
Oral ruxolitinib and baricitinib are in late-stage trials showing impressive repigmentation — especially in combination with phototherapy. Not yet widely approved for vitiligo but available off-label in some centres.
Non-scarring technique — skin cells are harvested, processed, and applied to the depigmented area. Excellent results on stable vitiligo, especially large body areas. Gaining popularity as a first-choice surgical option.
Traditional grafting methods using small donor skin plugs. Effective for focal, stable patches. Visible “cobblestoning” can occur with older techniques — MKTP has largely replaced these.
Raises a blister on normal skin to harvest a thin epidermal sheet. Good cosmetic outcomes on flat body surfaces. Less effective on hands, feet, or curved areas.
The most common clinical combination: topical tacrolimus or ruxolitinib applied before NB-UVB sessions potentiates the UV response. Many dermatologists consider this the most effective non-surgical approach.
Post-MKTP phototherapy sessions help stimulate and spread new melanocytes from the grafted area — improving coverage and longevity of results.
Emerging evidence suggests oral JAK inhibitors combined with phototherapy dramatically accelerate repigmentation — particularly for recalcitrant body vitiligo. Trials ongoing.
Permanently destroys remaining melanocytes in normally pigmented skin to match the depigmented areas. Used only when vitiligo affects >50% of body surface. Irreversible — a serious, considered decision.
Laser-based approach to remove remaining pigment in patches of normal skin. Less commonly used than MBEH but offers more precision for isolated areas.
Targeting upstream cytokines that drive the autoimmune attack. Monoclonal antibodies in Phase II trials show promise for halting vitiligo progression with fewer systemic effects than JAK inhibitors.
An α-MSH analogue that stimulates melanogenesis directly. Used in combination with NB-UVB in small trials — results in faster and deeper repigmentation. Being studied in larger cohorts.
Early-stage research into culturing and injecting autologous melanocyte stem cells. Potential game-changer for segmental and refractory vitiligo — but years from widespread clinical use.
What Determines the Best Treatment?
🌏 Extent & Location
Widespread vitiligo responds best to phototherapy or systemic therapy. Localised patches may respond to topicals or excimer laser alone. Face responds fastest.
🕑 Disease Activity
Active (spreading) vitiligo needs stabilisation first — often with oral mini-pulse steroids or JAK inhibitors — before repigmentation therapies are started.
🌞 Skin Type
Darker skin types (Fitzpatrick IV–VI) often show more striking repigmentation but also carry higher risk of post-inflammatory changes with some treatments.
📌 Patient Goals
Some patients prioritise halting spread. Others want maximum repigmentation. Treatment planning must align with realistic expectations and commitment level.
A note from dermatologists: There is no single “best” treatment for vitiligo. The most effective approach is always personalised — combining the right therapies for your vitiligo type, location, and activity status. Work with a specialist who stays current with the latest evidence.
Starting Treatment: Key Takeaways
See a specialist — preferably a dermatologist with vitiligo experience. Not all GPs are up to date on current options.
Establish stability — know whether your vitiligo is active or stable before choosing a repigmentation strategy.
Be patient — repigmentation is slow. Most therapies require 3–6 months of consistent treatment before meaningful results appear.
Ask about combinations — single therapies are often less effective than well-chosen combinations tailored to your case.
Consider clinical trials — if standard options haven’t worked, ask about access to investigational therapies at specialised centres.
Protect treated skin — use high SPF sunscreen on depigmented areas to prevent sunburn and protect new melanocytes during repigmentation.
Vitiligo treatment has come a long way.
From phototherapy to JAK inhibitors to surgical repigmentation — there are more evidence-based options available today than ever before. The right combination for you is out there. Start that conversation with your dermatologist today.
Explore the Full Treatment Guide →
